VNRX · VolitionRx Limited

-

Please sign in to comment on VNRX

1 Comment

Admin

3 years, 7 months ago

VolitionRx Limited is currently in a long term downtrend where the price is trading 17.1% below its 200 day moving average.

From a valuation standpoint, the stock is 851.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12741.3.

VolitionRx Limited's total revenue rose by inf% to $7K since the same quarter in the previous year.

Its net income has dropped by 44.4% to $-5M since the same quarter in the previous year.

Finally, its free cash flow grew by 413.9% to $9M since the same quarter in the previous year.

Based on the above factors, VolitionRx Limited gets an overall score of 2/5.

ISIN	US9286611077
Industry	Diagnostics & Research
Sector	Healthcare
CurrencyCode	USD
Exchange	NYSE MKT

Market Cap	102M
PE Ratio	None
Target Price	5.55
Beta	1.73
Dividend Yield	0.0%

ABOUT

VolitionRx Limited

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company was founded in 2010 and is based in Henderson, Nevada.

VNRX · VolitionRx Limited

-

VolitionRx Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest VolitionRx Limited using a moving average strategy